Extrapolation relationships are of keen interest to chemical risk assessment where they play a prominent role in translating experimentally derived (usually in animals) toxicity estimates into estimates more relevant to human populations. A standard approach for characterizing each extrapolation relies on ratios of pre-existing toxicity estimates.
Introduction
Most determinations of chemical safety are based on animal experiments and must invoke extrapolation relationships to derive a toxicity estimate relevant to human populations. Consequently, approaches for characterizing each extrapolation relationship are of keen interest.
A standard approach tries to discern each relationship from a dataset formed from ratios of pre-existing toxicity estimates. For example Baird et al. [1] found 51 chemicals for which ratios of chronic/subchronic toxicity could be formed, and used them to study subchronic to chronic extrapolation. Several others have applied the same empirical approach to look at this and other extrapolations (e.g., between species, routes of administration, and e®ect endpoints).
Although sensible
1 , this \ratio approach" can be undermined by several sources of error.
Owing to the relatively small number of chemicals for which ratios can be assembled, inferences are subject to¯nite sample error. Moreover, measurement error a®ects each of the estimates forming the ratios. Additional error can arise due to the patchwork of experimental conditions under which the various toxicity estimates were obtained. To date, applications of the approach have overlooked these errors.
This paper focuses on better characterizing informativeness. It builds upon a previous paper [2] , which examined ratios of no-observed-adverse-e®ects-levels (NOAELs) | a toxicity estimate used in noncancer risk assessment. Here we examine ratios of a di®erent toxicity estimate, the benchmark dose (BMD). This alternative estimator is widely thought to have better statistical properties than its NOAEL counterpart [3, 4, 5, 6, 7] . A motivating question is whether BMD ratios can transcend the substantial limitations found for NOAEL ratios [8, 2] .
Our approach involves modeling the way BMD ratios are generated in practice and then using the model to study the impact of the aforementioned errors. For illustration, the analysis focuses on the problem of extrapolating between mouse and rat toxicity. The intent, however, is to be instructive for the more general use of BMD ratios.
We pay special attention to dose selection, a fundamental aspect of experimental design 1 The approach presumes that the true underlying extrapolation relationship is well represented by a proportionality constant with some random variation (perhaps due to inter-chemical heterogeneity). Ratios are inappropriate for studying other types of relationships.
that can in°uence the quality of each BMD estimate. The practice of dose selection is an art, involving a certain degree of guesswork about the doses at which the agent in question will yield the most informative responses, and it is unlikely to be optimal across all experiments.
To explore this complicated issue, we o®er two simpli¯ed models of dose selection and examine their implications.
The paper begins with a background section which: i) summarizes the process by which BMD ratios are generated; ii) speci¯es the restricted form of extrapolation relationship considered in this analysis; and iii) introduces the framework we use to de¯ne informativeness.
Next, the methods section introduces an idealized model of the data-generating process (DGP)
for BMD ratios and then proceeds to describe assumptions needed for quantitative modeling.
Our simulation approach is then described. The results section begins with the idealized case, comparing closed-form and simulation based results, and then presents results for a less idealized model of the DGP. Finally, results are interpreted, wider implications are identi¯ed, and recommendations are made for improving future extrapolation studies.
Background
Before examining the ability of measurements to reveal the underlying property, it is useful to clarify: i) the nature of the measurements; ii) the nature of the underlying property being measured; and iii) the notion of informativeness used in gauging correspondence between the two.
The Measurement and its Data-Generating Process
Fig 1 illustrates a hypothetical application of the ratio approach. It examines the case of mouse to rat extrapolation. After mouse and rat toxicity estimates are gathered for a set of chemicals, the paired (by chemical) data are checked for consistency with the assumption of a proportional relationship (see Fig 1A) . Upon con¯rmation, ratios are calculated from the paired data to obtain the empirical distribution shown in Fig 1B. Its central tendency (solid vertical line) is used to infer the systematic di®erence in toxicity between mice and rats, and its spread (variance) is used to infer the inter-chemical heterogeneity of that di®erence. In practice, geometric measures of central tendency (Geometric Mean, GM) and spread (Geometric Standard Deviation, GSD) are preferred, because of the consistency of observed ratios with lognormality and their restriction to non-negative values.
The Data Generating Process
In modeling how the empirical distribution ( Fig 1B) arises in practice, we face several challenges. The Data-Generating Process (DGP [9, 10, 11] ), entailing any factor (step) capable of in°uencing the individual BMD estimates (typically these are measured independently), can be complicated. We only consider three key steps:
1. The in°uence of experimental design. Dose selection is our primary concern, but we also consider other aspects such as the number of animals per study. These three steps are included in our model of the DGP, which is then used to study the informativeness of BMD ratios. Modeling the¯rst two steps is particularly challenging because each is a®ected by traditions, precedents, or regulatory standards, which may go undocumented and may be inconsistent across BMD estimates. A more complete discussion of the DGP for BMD ratios is provided in Ref [8] .
The BMD Estimate
A BMD can summarize either continuous (e.g., average body-weight change) or quantal (e.g., fraction of animals surviving) experimental outcomes, and can re°ect either \best" or lowerbound estimates [4, 12, 13, 6] . We restrict attention to best estimates (Maximum Likelihood Estimates, MLE) obtained from quantal data and denote them using the standard notation, EDq; where q denotes the quantal level response of interest (a value of 10%, 5% or 1%, is typical). Focusing on the mouse/rat example, we use the random variable µ to denote the pertinent ratio of BMDs,
where the subscripts m and r are used to index mouse and rat attributes and theÊDq's, being estimates (as denoted by the hats), are random variables.
We are interested in both asymptotic and¯nite-sample properties of µ. The asymptotic, or large-sample, properties suggest the best that one can do as sample size (number of ratios) becomes e®ectively in¯nite. In reality samples are¯nite; thus¯nite sample error is of interest.
The Property
The property is an underlying biological relationship, presumed to exist between the two toxicity endpoints of interest (mice and rats in our case). A standard practice assumes a proportionality relationship,
where ED q denotes the true e®ect-dose, and £, the \constant of proportionality," de¯nes the property.
The property, £, is conceptualized as a random variable, representing the net result of a systematic di®erence in toxicity between mice and rats as well as inter-chemical heterogeneity in that di®erence. Systematic di®erences could accrue from the gross di®erences between species (e.g., rats are roughly 10-fold larger by mass), while inter-chemical heterogeneity could result if the chemicals invoke di®erent toxicokinetic and or toxicodynamic mechanisms. In practice doses are often scaled, that is expressed in units which are intended to adjust for the systematic di®erence, so the observed systematic e®ect represents only that which is unaccounted for by the chosen scaling rule.
Because the interchemical heterogeneity is conceptualized as arising from multiplicative deviations from the norm, a lognormal distribution is a sensible choice for representing £.
where GM £ denotes the geometric mean, and GSD £ denotes the geometric standard deviation. These parameters correspond to the systematic e®ect and inter-chemical heterogeneity,
respectively.
When the mouse and rat dose-response relationships are parallel, the property £ applies to all e®ect levels, i.e., to any choice of q (See Ref [14, 8] for more detail). That is,
We restrict our analysis to this special case of parallelism, noting that it is a standard assumption in research on comparative potency [15, 16, 17, 14, 18, 19] , but further noting that the implications of non-parallelism deserve closer attention in future research.
De¯ning Informativeness by Analogy to Calibration
A basis for comparing the property £, with its' measurement, µ, is needed. Rather than comparing distributions directly, it is more convenient to compare their associated parameters (GM £ versus GM µ and GSD £ versus GSD µ ).
We use the concept of calibration to evaluate informativeness. Calibration usually involves: i) engineering a series of standards (e.g., standard weights in gravimetric analysis) with a known value of the quantity being measured, ii) subjecting each standard to replicate measurements; and iii) plotting the replicate measurements, or some summary thereof, against their associated standards. This yields a calibration curve, well suited for conveying the concept of \informativeness," which we de¯ne as connoting not only accuracy and precision but also how each depends on the magnitude of the underlying standard (truth) [8, 2] . Our analysis uses a similar process to gauge the informativeness of an empirical distribution ofÊDq ratios, where the modeled \measurement device" encompasses the entire data-generating-process (DGP).
Figures 2a through 2c illustrate three potential calibration results. In Fig 2a, Thus, the procedure for constructing a simulated calibration curve is identical to conventional procedures, the only di®erence being that replicate measurements are generated by simulation rather than actual experiment.
Methods
We use closed-form and simulation based approaches to model the DGP. The closed-form approach is examined¯rst. Then, the assumptions necessary for quantitative modeling are introduced and¯nally the more generally applicable simulation approach is described.
The Idealized Data Generating Process
Under certain idealized conditions, a closed-form expression can be derived for the large sample GM or GSD estimate [8] . The modeled bioassays (mouse and rat) must be \identical" to each other up to a scalar transformation in dose (applied to their test doses and underlying doseresponse curves). Under these conditions, Eq 1 can be re-expressed as,
where £ is the property of interest and u m and u r representÊDqs conditional upon a standardized set of conditions (i.e., experimental design and dose response attributes). The standardization implies that u m and u r are independent and identically distributed (iid) with one
another. The large sample GM µ can therefore be expressed as,
where, E[log (u m ) ¡ log (u r )] = 0, because u m iid » u r . The expression reveals that under idealized conditions large sample estimates of the systematic e®ect are unbiased.
Similarly, applying the variance operator and appropriate transformations to Eq 4 obtains an expression for the large sample GSD µ .
where GSD u = exp ( Both Eq's 5 and 6 provide important qualitative insight 2 , however, only the expression for GM µ (Eq 5) provides complete quantitative insight for large sample results (i.e., since additional analysis is required to quantify GSD u ). In addition, these expressions do not address¯nite sample imprecision. To get more complete insight and to examine less idealized DGPs, we turn to simulation.
A Simulation Approach
This section begins by outlining several categories of assumptions underlying our simulation analysis. Although logically unrelated to the property of interest, £, and therefore theoretically exogenous, these assumptions a®ect the`lens through which we view' the property and therefore must be speci¯ed to fully characterize the DGP. Two factors including dose selection and the BMD estimation protocol, are given special attention. Several others, including doseresponse and experimental design factors, are referred to collectively as`contextual factors' and examined¯rst.
Dose-Response Relationship
The response data used to estimate eachÊDq must be generated from the underlying doseresponse relationship. A three-parameter Weibull model is used to represent this relationship for both mice and rats. The model expresses the expected response (fraction of animals with adverse e®ects), denoted R, as
where d is the dose, ® corresponds to a background response rate, ED 50 is a`location' parameter, k determines dose-response shape, and log () is to the base e throughout.
The inclusion of ® in Eq 7 allows for nonzero background response. We assume it to be equivalent in both species (® m = ® r ).
Adjusting the location parameter (ED 50 )¯xes the 50% response of the underlying doseresponse curve, enabling the dose-response curve to be shifted. Adjusting the shape parameter k achieves varying degrees of non-linearity | as k is increased (for k > 1) the dose-response curve becomes increasingly sub-linear.
As described earlier (Section 2.2) parallel dose-response relationships are assumed throughout this analysis. The restriction, implying equivalent dose response shapes (i.e., k m = k r ), should favor informativeness.
In this analysis, only the relative location of the mouse and rat dose-response relationships matters. Thus for the purposes of analysis, the rat ED 50 is treated as the frame of reference and assigned an arbitrary value (ED 50r = 1). With this de¯nition, Eq 2 dictates that ED 50m = £.
Experimental Design Factors
Two aspects of experimental design have the potential to signi¯cantly in°uenceÊDq's and associated ratios: 3 the number of animals in each dose group and dose selection.
We assume that the number of animals (denoted n a ) is the same in each dose group for both mice and rats. For the base case, calculations are run with n a = 20 animals.
A mouse (or rat) bioassay is assumed to consist of a control group (with dose d 0 = 0) and a set of n d dosed groups arranged symmetrically on the logarithmic scale around their central test dose, denoted d c . Two further assumptions are required to fully specify the test doses.
These include i) the dose spacing, denoted s, which we de¯ne to be the geometric spacing between the highest and central test doses (d max =d c ), and ii) the general strategy for centering the test doses in each of the bioassays. The latter amounts to specifying d c for both mouse and rat bioassays.
Mouse and rat bioassays are assigned equivalent n d and s. Plausible values for these parameters are readily based on general practice [21, 22, 23, 24, 25, 13] .
The issue of dose centering is more complicated. Any model of this process must re°ect not only the general strategy used by the experimenter to center test doses (for each chemical), but also its success. We o®er two simpli¯ed models. The¯rst, referred to as \enlightened dose centering," was implicitly assumed in Section 3.1's derivations for the idealized DGP.
The second, referred to as \default dose centering," is intended to examine the implications of less optimal dose centering, more typical of practice.
Both models make use of a working de¯nition for ideal dose centering wherein the experimenter is assumed to place the central test dose, d c , exactly at the tested chemicals' underlying
The enlightened model presumes ideal centering in both mouse and rat bioassays (across all chemicals).
The default model presumes ideal centering only for the rat bioassays. For mouse bioassays experimenters are assumed to set d c m = d c r which would seem a sensible recourse when there 3 Other experimental design decisions such as caging arrangement, feeding protocol, etc are well known to a®ect experimental outcomes [20] , but are not considered, to simplify discussion. 4 We do not claim that centering test doses exactly at the ED 50 is optimal (this would depend on other factors such as dose response shape). We simply use it as a reasonable working strategy.
is no chemical speci¯c evidence to prompt otherwise. Being centered around the rat ED 50
(or equivalently d c r ), the mouse doses will be`misplaced' whenever ED 50r is a poor proxy for ED 50m . The misplacement will generally involve a random component (since GSD £ > 1), and will involve a systematic component when GM £ 6 = 1.
Replicate datasets
To re°ect the impact of measurement error on eachÊDq estimate, we use Monte-Carlo simulation [26] . It involves generating replicate measurements, subject to identical experimentaldesign and dose-response parameters. Each replicate's outcome is modeled as the number of animals showing a response (e.g., death) in each dose group and is denotedx, which includes the set of n d + 1 responses (i.e., one per dose group). It is the variation inx owing to chance that is responsible for measurement error. This is captured by modelingx as,
x j » Bin(n a ; R j ), for j = 0; 1; : : : ; n d + 1. That is, the response in the jth dose group is drawn from a binomial distribution where the \success probability," R j , is the expected response in the jth dose group determined by evaluating the true dose-response function (Eq 7) at dose d j . A total of N repx 's, is generated per experiment to simulate the impact of chance.
BMD Estimation
For each replicate, anÊDq estimate is obtained using maximum likelihood estimation (MLE) to¯t a model to the dose-response data. In our analysis, the model form¯tted to each simulated dataset is chosen to be identical to the three parameter Weibull model de¯ning the truth (Eq 7). In reality, less compatibility between true and¯tted relationships is expected.
Since our analysis requires estimating parameters for a large number of datasets (approximately 50; 000 per large sample estimate) we developed our own algorithm for Maximum Likelihood estimation. The procedure needs to be automated, reliable, and e±cient and also needs to allow parameters to be constrained (since standard practice precludes negative Weibull parameters). To do this, the Amoeba Downhill algorithm [26] was modi¯ed for non-negativity constraints, and an automated method for specifying starting values for the optimizatioǹ search' was developed [8] . The automated method, which exploits the delta method [27] , yields rapid and reliable convergence [8] . Unlike some analysts, we do not constrain the shape parameter to be greater than 1 (some restrict k · 1 so as to preclude supra-linearity [4] ).
Once the constrained MLE parameters are obtained, the¯tted model is used to backcalculate the dose associated with an extra risk of q percent [4, 29] . De¯ning extra risk as,
where the hat notation is used to identify MLE parameter estimates. In this analysis,ÊDq's are calculated for an extra risk of 10 %, thereby obtaining anÊD 10 .
Not all datasets are suitable for standard maximum likelihood estimation. Here, two classes of unsuitable datasets are considered: (a) those failing a test for positive trend (referred to as \non-signi¯cant"), and (b) those yielding unbounded MLE parameter estimates (referred to as \un¯ttable"). 5 Any analysis must specify a protocol for dealing with such datasets. We assume that they are dropped from further analysis. This`drop-protocol,' which has the potential for distorting the DGP, is just one of several possibilities. One might also defer to another related dataset, invoke alternative e®ect estimation techniques (e.g., NOAEL estimation as suggested in Ref [7] ), assign \working values" to the dose-response data so as to avert the di±culty [30, p. 130], or even re-do the experiment, perhaps with di®erent dose levels.
To identify \non-signi¯cant" datasets we use a Cochran-Armitage trend test [14] . Datasets either failing to exceed the signi¯cance criterion (p · 0:05) or demonstrating negative trend are dropped from further analysis. Though intended to mimic practice (see for e.g., Barnes et al. [7] who advocate signi¯cant trend as a prerequisite for BMD estimation), the screen is also partially motivated by pragmatic concerns associated with convergence of our MLE algorithm.
The retained datasets are then examined to screen out un¯ttable datasets which are, in the case of¯tting Weibull models, characterized by an unbounded MLE for the shape parameter [30, 31, 18] . Un¯ttable datasets are identi¯ed (see Ref [8] for convenient criteria)
and dropped from further analysis.
Methods for Simulating a Calibration
Given a particular set of speci¯ed \contextual factors," calibration curves are plotted to explore informativeness. The curves are constructed by simulating replicate bioassay experiments for each calibration standard (i.e., speci¯cation of the true distribution of £) and tracing out the DGP steps for each replicate. With a su±cient number of replicates, the outcomes provide a large-sample approximation of f (µ). These distributions, which correspond to the schematic distributions appearing in Fig 2, play a fundamental role in the construction of our calibration curves.
Because each f (µ) is a function of the distribution ofÊDqs observed in mice and in rats,
we begin by describing the generic procedure for obtaining a Monte-Carlo approximation of f (ÊDqjED 50 ); where the distribution is conditional on a¯xed ED 50 .
Sampling distribution for BMD (ÊDq)
The procedure for computing f (ÊDqjED 50 ) involves: (i) generating N rep replicate datasets,
x as described in Section 3.3; (ii) discarding all replicates that are deemed unsuitable (see The sample distribution f (ÊDqjED 50 ), corresponding to the case of ED 50 = 1 is of particular interest. We refer to it as the \unit distribution," denoting it f (u). It corresponds to thê EDq sample distribution modeled for rats (since ED 50r = 1). In the case of enlightened dose centering, it also applies (with simple scalar transformations) to all mouse bioassays.
Assembling the Sampling Distribution for Ratios
The sampling distribution forÊDq ratios, f (µ), can be obtained by combining the mouse and ratÊDq sampling distributions. The former, f (ÊDq r ), is simply the aforementioned unit distribution, f (u).
Obtaining the mouse distribution, f (ÊDq m ), is more complicated because there is no single ED 50m . Instead the inter-chemical heterogeneity speci¯ed in our model implies a distribution for ED 50 m consistent with £. The mouse distribution, f (ÊDq m ), requires \averaging" condi-tional distributions f (ÊDq m j£) across £, where the distribution of £ was given in Eq 3. This is implemented using a statistical procedure called Monte-Carlo integration. The result is a numerical approximation of f (ÊDq m ) consisting of a set of
realizations. Again the prime notation indicates that N rep may be reduced after discarding unsuitable datasets.
Once the sampling distributions for the mice and rats have been approximated, their respective realizations are combined using independent resampling (N resamp times with replacement) to approximate f (µ). Independent resampling is appropriate because of the way every rat bioassay is modeled; each is standardized (i.e., ED 50r = 1) and consequently their outcomes are independent of one another as well as their counterpart mouse outcomes.
All \observed" summary statistics are computed from the approximation of f (µ). Large sample estimates of central tendency (GM) and spread (GSD) are readily computed using standard methods, while bootstrap techniques are applied to study the¯nite sample imprecision in either estimate (detail is available [8, 2] ). 
Results
We examine the informativeness of GM and GSD estimates by presenting results in the form of calibration curves. The curves plot simulated observations versus their counterpart truths (standards). Here, each observation represents either a GM or a GSD estimate, while the speci¯ed value for its counterpart (GM £ or GSD £ respectively) acts as the standard.
In order to convey informativeness both large and¯nite sample results are plotted. Large sample estimates are plotted using +s, while the imprecision associated with a more realistically sized sample (n ratio = 50) is examined using 95 % con¯dence intervals (plotted using triangle symbols).
To help in gauging bias, a one-to-one reference line is plotted on each graph. It represents an ideal calibration curve, i.e., the case for which the estimate perfectly tracks the truth. A calibration curve falling on this line suggests an unbiased estimator; an implicit assumption when GM or GSD estimates are taken at face value. Curves falling o® this line may still be informative provided they show a trend which is not obscured by the¯nite sample error.
Calibrations for the enlightened and default models are run separately to look at the in°uence of dose centering. All primary analyses assume a base-case set of contextual factors including, a background rate of ® = 0:05, a dose response shape of k = 2, a number of animals per dose group of n a = 20, a dose spacing of s = p 10, a number of dosed groups of n d = 3, and (in the case of a GM calibration) a nominal value of GSD £ = 2:5 (or GM £ = 1:0 in the case of a GSD calibration).
Enlightened Dose Centering
The enlightened case is of interest for two reasons. First, it provides an upper-bound on the informativeness ofÊDq ratios. Second, being subject to the closed-form solutions derived in Section 4.1, it provides an opportunity to cross-check our simulation algorithm.
GM Calibration
The calibration shown in Fig 3 examines 
GSD Calibration
Turning to the issue of inter-chemical heterogeneity, Fig 4 examines 
Default Dose Centering
The default model explores the implications of imperfect dose centering. When severe, the imperfection can increase the number of unsuitable datasets, which in turn (by virtue of our drop-protocol) causes the censoring ofÊDq's and associated ratios. The censoring can cause a distinct pattern in the calibration curves; a plateau-e®ect (i.e., curve°attens out, relative to the one-to-one line), which a®ects both GM and GSD calibration curves (in the default case), and undermines informativeness.
To conserve space we present results only for GSD calibrations (results for GM calibrations, similar to those for GSDs, are available [8] ).
Recognizing the prominent role of censoring we have added a diagnostic bar-plot to each calibration curve. Solid vertical bars are used to indicate the fraction of censoring associated with each observed GSD. It is a rather crude diagnostic because it lumps all censoring together [8] . More sophisticated censoring diagnostics will be explored in future research. 
GSD Calibration: Default

Dependence Upon Contextual factors
The results presented above demonstrate that informativeness strongly depends on dose centering. Next we explore the impact of varying the contextual factors.
Enlightened Case
The closed form expressions derived for the enlightened case prove that some estimation properties are independent of contextual factors. Namely, GM and GSD estimates remain asymptotically unbiased and upwardly biased, respectively, regardless of context. However, the extent of GSD bias varies with context as does¯nite sample imprecision. Both depend on measurement error (i.e., GSD u ) in an intuitive manner.
Default Case
The sensitivity to contextual factors is not as easy to gauge under default centering because the more prominent role of censoring, complicates matters. Predicting sensitivity for a particular contextual factor requires anticipating the net result of its impact on both \measurement error" and censoring; impacts which can be opposing. To illustrate the extent of sensitivity we present one set of results for the informativeness of GSD estimates (results for GM estimates are presented elsewhere [8] ). In reality, informativeness would be even worse than appears in Fig 7 . The diminishing informativeness with increasing k is less intuitive. Given the presumed estimation protocol, increasing k (increasing step-like shape) increases censoring by increasing the fraction of un¯ttable datasets. The plateau e®ect ensues.
The bar-plots in Fig 7, a±rm the association between censoring and poor informativeness.
Less informative curves are characterized by higher censoring (i.e., see bottom row of panels, where associated barplots indicate censoring ranging from 54% to 95%), whereas the most informative curve shows the least (top-right panel indicates censoring ranging from 0.0% to 10%).
Within panels the association is not as pronounced (e.g., panel k5 n20). Further re°ection suggests that the weak association may be attributed to the crude nature of our diagnostic.
The impact of censoring strongly depends on where (in the uncensored distribution) that censoring occurs, a feature missed by a measure which lumps together all censoring.
The extreme censoring characterizing some panels in Fig 7 ( e.g., the bottom row) raises a question. Can panels exhibiting such high censoring have a bearing on actual practice ? It seems implausible that testing programs would persist in the face of so much censoring. The relevance of each panel in Fig 7 to practice, may therefore vary, even though each is a function of plausible contextual factors.
Discussion and Conclusions
The ratio approach for characterizing extrapolation relationships overlooks several sources of error which are of interest in the evaluation and improvement of methods for chemical risk assessment. We found the informativeness of the approach to be su±ciently limited to undermine the current practice of taking results at face-value. Future applications of the ratio approach should attempt to quantify and adjust for bias and imprecision. We o®er a standard approach for gauging imprecision, and suggest that more complicated techniques will be required to gauge bias.
Interestingly, BMD ratios do not necessarily outperform NOAEL ratios, as one might rst suspect. A preliminary comparison of results for NOAEL ratios [2] , and their BMD counterparts, is equivocal [8] . Depending on the context, NOAEL ratios can be more or less informative.
We begin this discussion by summarizing our results. We then carefully scrutinize our model, and conclude that it is basically sound and provides a good starting point for quantifying bias and imprecision. The scrutiny is revealing. It suggests several ways to improve the ratio approach and reveals that our work has wider implications.
Our modeling results show substantial imprecision and bias in GM and GSD estimates.
Although the extent of these errors is found to vary with several factors, imprecision is consistently non-negligible.
Distinct di®erences in calibration curve patterns are observed between the two (default and enlightened) dose centering models. Only default centering exhibits plateau-e®ects. The resulting potential for downward bias a®ects both GM and GSD estimates. In contrast, the enlightened case has unbiased GM estimates and only upward bias in GSD estimates.
Factors beyond dose centering also have substantial e®ects on calibration properties. Fig 7 and additional analyses, reveals sensitivity to all contextual factors. These factors need to be taken into account when interpreting BMD ratios.
Some of our calibration curves (e.g., Fig 7, upper right, i.e., k1 n50) suggest that the ratio approach can be informative. But our results hide an additional source of uncertainty. Each curve presumes that all contextual factors are identi¯able (known with reliable precision), but in reality some, e.g., dose response shape (k), are poorly known. This translates into uncertainty about which calibration curve applies, clouding the estimation of bias.
Two calibration curve features, the plateau e®ect and the propensity for an upwards GSD bias, are explained by censoring and measurement error, respectively. Simplistically, their impacts can be described as subtracting and adding variation, respectively, and thus have a predictable in°uence on imprecision as well. Censoring plays a more in°uential role under default centering, while measurement error plays a roughly comparable role under both cen-tering models. Owing to our drop-protocol, censoring is a direct result of unsuitable datasets, and thus increases with poor centering. Intuitively, measurement error varies inversely with statistical power.
The relevance of our results is contingent on how faithfully we have captured the true DGP. E®orts have been made to use only plausible assumptions, however, some are di±cult to verify.
In most cases of ambiguity, we have made assumptions with the intention of favoring informativeness. For example, we assumed that mouse and rat dose response curves are parallel and that the true and¯tted dose response relationships are compatible (both Weibull).
Although, reality is likely to deviate from these assumptions, it is likely to do so in a way that worsens informativeness. Not all of our assumptions necessarily favor informativeness.
Two, including the drop-protocol, and our implicit neglect of multi-comparisons, deserve closer consideration.
The drop-protocol, which automatically censors each unsuitable dataset, seems like a worse-case assumption. How can one do worse than outright censoring? Yet using an alternative protocol, such as reporting the NOAEL (where obtainable) for each unsuitable dataset, would not necessarily improve informativeness. A NOAEL imputation protocol has its own errors [2] , and does not work for all datasets. Thus censoring and the attendant plateau e®ect is likely to exist even if wiser protocols are practiced.
Our analysis has overlooked the issue of multi-comparisons. It implicitly assumes that ratios are formed between speci¯c e®ect endpoints in the mouse and rat bioassays, and not, as is common, between the most sensitive (or pivotal) endpoints. This added stipulation for \most sensitive" would require additional steps in our model of the DGP. Informativeness may or may not improve, depending on dose centering and how the dose response relationships are related across endpoints. This will be the subject of future research.
In Section 4.3.2 we questioned how much censoring could go unchecked in practice. Some clues can be obtained from past studies. For example, Faustman et al. [13] reported that among 2; 000 reproductive bioassay endpoints (not all independent), 43 % precluded the identi¯cation of a Lowest Observable Adverse E®ect Level (LOAEL). Indicative of the prevalence of the nonsigni¯cant class of unsuitable datasets, this suggests that censoring on the order of 50% is conceivable (provided drop-protocol applies). Un¯ttable datasets, would only add to this percentage. Future work will explore this issue in more detail.
The ratio approach can be improved in several ways. Some actions can improve inferences from pre-existing ratio datasets, while others can assure that more complete information is recorded, or minimize the errors a®ecting the approach.
The bias and imprecision in GM and GSD estimates must be estimated. A simple solution exists for gauging imprecision: namely bootstrap techniques can be applied to the raw ratio data in much the same way as we did in our simulation. Bias, on the other-hand must be predicted.
Our results demonstrate that bias depends on several factors. Addressing these dependencies requires more information about each of the contributing bioassays. At the very least each BMD should be accompanied by its raw dose response data. This facilitates wiser and/or more consistent BMD estimation protocols. Additional information should be collected to account for in°uential co-factors. Information is: most readily available for experimental design factors (e.g., n a , n d , s); discernible, but with poor precision, for dose response factors; and, generally unavailable for dose centering and BMD estimation protocols.
Predicting bias is complicated. The problem simpli¯es under enlightened dose centering where only bias in the GSD is of concern (GM estimates are unbiased). In this case, the GSD bias can be determined with the aide of Eq 6, after estimating GSD u (using either simulation, see Section 3.3, or, if certain asymptotic conditions hold, the delta-method [27] ).
Accounting for bias will be more di±cult in practice. Imperfect dose centering will complicate matters with the plateau e®ect. Moreover, the patchwork of contextual factors expected in practice will necessitate averaging calibration properties across the patchwork. New methods, perhaps building upon ours, will be required. Notably, some occasions, namely hypothesis testing, require more detail than simply the imprecision and bias of the estimate. The precision and bias under the null must also be known (or estimated). Detail of this kind requires modeling the DGP and producing a calibration curve or some simplifying assumptions.
Not all recommendations revolve around better characterizing imprecision and bias. Steps aimed at a more strategic design of future bioassays can mitigate the errors. Measurementerror can be reduced by increasing the statistical power of the bioassays (e.g., increasing n a , or n d ). This has the added bene¯t of reducing the number of non-signi¯cant datasets and thereby mitigating censoring. Relaxing the signi¯cance criteria (p-value) could have a similar e®ect. But, perhaps the most e®ective way to mitigate censoring is to aspire towards enlightened dose centering. The feasibility of these recommendations varies. In the case of increasing statistical power, opportunity costs can be prohibitive, while assuring enlightened dose centering, possibly requiring expensive dose ranging studies or sequential designs 6 , has, in addition, its practical limits [8] .
Although we examined the hypothetical case of mouse to rat extrapolation, our analysis has wider implications. The range of input values and assumptions explored is compatible with most chronic, sub-chronic, and (arguably) acute bioassays. Thus the general assertion, that imprecision and bias can not be overlooked, holds for essentially any application of the ratio approach to quantal data (e.g., to explore route to route, endpoint to endpoint, subchronic to chronic, and other extrapolations). Indeed, the roots of the problem (measurement error and censoring) are fundamental and likely to have broader implications. They are likely to a®ect most other empirical extrapolation approaches, including`non-linear' analyses of ratios [38] , regression studies extending beyond pair-wise comparisons [39, 40] , and other studies exploring relationships between alternative toxicity estimates [41, 42, 43, 44, 45] . They also have implications for studies of optimal design and studies comparing the relative merits of alternative toxicity measures (e.g., BMD versus NOAEL). Such studies need to allow for the inherent unreliability of dose centering and specify what is to be done with unsuitable (e.g., insigni¯cant) outcomes.
Generalize-ability to toxicity estimates drawn from continuous or categorical data is a topic of future research. Our analysis only dealt with quantal data, which may accentuate censoring.
Slob and co-workers [46, 47] have independently pointed out the potential for upwardly biased GSD estimates and¯nite sample error, while Faustman (reported in [21] ) has expressed other qualitative concerns. Our analysis takes a more quantitative tact, demonstrating that the errors are non-negligible and revealing the key in°uence of dose centering, unsuitable datasets, and the estimation protocol.
We are not the¯rst to examine the in°uence of dose selection on extrapolation studies.
Several papers have debated whether the correlation observed between mouse and rat cancer potency's, is merely an artifact of a coordinated choice of test doses [48, 49, 50, 38, 51, 52, 53] .
The artifact argument is explainable by the plateau e®ect and thus compatible with our default case. Our approach may help in better establishing the informativeness of the observed correlations.
Understanding the DGP and using a calibration construct to explore its implications has proven useful in this work. The same approach could be applied to other steps in regulatory toxicology, where an actual calibration is often impossible or prohibitive, and where an analyst may be prone to a±rming the consequent. Considering the DGP suggests the distribution of observations to be expected under rival hypotheses | not just the one presupposed | and in this way supports more appropriate inference. We hope to apply this same general approach in future research.
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